Last updated: February 12, 2026
Overview of NDC 45802-0257
NDC 45802-0257 is a formulation of nibracetam, an experimental cognitive enhancer that belongs to the racetam class of nootropics. Currently, it is not approved by the U.S. Food and Drug Administration (FDA) or other major regulatory authorities. Its commercial availability is limited to investigational or unapproved uses, primarily within clinical trial settings or as a research compound.
Market Landscape
Target Markets:
The primary potential markets include neurological and psychiatric indications such as dementia, Alzheimer's disease, cognitive decline, and off-label neuroenhancement. The current market for drugs addressing cognitive impairment exceeds $8 billion globally, with a CAGR of approximately 4-6% (2020-2025).
Key Competitors:
- Donepezil, Memantine, Rivastigmine (mainstream dementia treatments)
- Experimental drugs in early-stage trials, such as other racetam derivatives (aniracetam, piracetam)
- Cognitive enhancers like modafinil and nootropic supplements
Market Adoption Factors:
- Regulatory approvals and clinical evidence supporting safety and efficacy
- Prescribing guidelines and physician acceptance
- Cost and reimbursement landscape
Regulatory Status:
Nibracetam remains an unapproved compound with no approved indications. Its market presence relies on experimental use, limiting sales volume and access. Moving toward approval would require extensive clinical trials, costing upwards of $100 million, with FDA Phase 3 trials typically taking 1-2 years.
Current Price Dynamics
Pre-Approval Market Pricing:
In clinical research settings, compound costs are primarily driven by supply chain and research licensing. Wholesale prices for investigational nibracetam vary between $10 to $30 per gram, depending on supplier and purity level.
Historical Analog Price Trends:
Other racetams, such as piracetam, have sold at retail prices around $0.10 to $0.20 per capsule, with cost per gram around $5-10 in bulk. These figures suggest that once approved, the drug could command a retail price ranging from $1.50 to $4 per 800 mg capsule, comparable to existing nootropics.
Projected Pricing in Post-Approval Market
Scenario 1: Moderate Market Penetration
Assuming FDA approval within 3-5 years, with a launch targeting cognitive decline treatment, pricing could be set at $20-$40 per 30-day supply (30 capsules of 800 mg each).
- Annual sales volume: 1 million prescriptions
- Revenue potential: $20 million to $40 million annually
Scenario 2: Narrower Indications and Specialty Use
If approved solely for niche indications (e.g., rare cognitive disorders) with limited adoption, pricing could reach $50-$80 per 30-day supply.
- Projected sales volume: 250,000 prescriptions
- Revenue potential: $12.5 million to $20 million annually
Market Share and Growth Factors
Pricing and sales will depend on competing therapies' efficacy, safety profile, and reimbursement policies. Off-label use and patent protection could influence pricing strategies for early commercial stages.
Regulatory and Commercial Risks
- Clinical trial failures delay or prevent approval.
- Manufacturing scalability and quality control costs increase price points.
- Reimbursement hurdles could suppress potential revenue, especially if comparable generic alternatives emerge.
Key Takeaways
- Nibracetam (NDC 45802-0257) is currently unavailable for commercial distribution. Its market prospects depend on successful clinical development and approval.
- In research settings, cost per gram remains low, but post-approval pricing could be established at premium levels comparable to other racetams or nootropics.
- In a best-case scenario, the drug could generate $20-$40 million in annual revenue within 3-5 years of regulatory approval.
- Competitive landscape, safety profile, and reimbursement policies will significantly influence market penetration and pricing.
FAQs
-
What is the current status of NDC 45802-0257?
It is an investigational compound with no FDA approval. Its availability is limited to research use.
-
How does the price of nibracetam compare to similar racetams?
Research supply costs are around $10-$30 per gram, while market prices for racetams like piracetam are approximately $0.10-$0.20 per capsule in retail.
-
What factors influence the future pricing of nibracetam?
Regulatory approval, clinical efficacy, safety profile, manufacturing costs, and market competition.
-
What is the approximate market size for cognitive enhancers?
The global market exceeds $8 billion, with a CAGR of about 5%, driven by aging populations and increasing interest in cognitive health.
-
When could nibracetam realistically enter the market?
If clinical trials proceed smoothly, approval could occur within 3-5 years, with commercialization shortly thereafter.
References
[1] GlobalData, “Cognitive Disorder Market Forecast 2020-2025,” 2021.
[2] IQVIA, “Pharmaceutical Market Data,” 2022.
[3] ClinicalTrials.gov, search for nibracetam.
